| _version_ |
1797285892686086144
|
| collection |
DOAJ
|
| first_indexed |
2024-03-07T18:09:59Z
|
| format |
Article
|
| id |
doaj.art-c86aa9520af74cd9b39eb3699f1f014f
|
| institution |
Directory Open Access Journal
|
| issn |
2572-9241
|
| language |
English
|
| last_indexed |
2024-03-07T18:09:59Z
|
| publishDate |
2018-10-01
|
| publisher |
Wiley
|
| record_format |
Article
|
| series |
HemaSphere
|
| spelling |
doaj.art-c86aa9520af74cd9b39eb3699f1f014f2024-03-02T07:47:33ZengWileyHemaSphere2572-92412018-10-0123610.1097/01.HS9.0000547935.17200.58201810003-00092T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)http://journals.lww.com/10.1097/01.HS9.0000547935.17200.58
|
| spellingShingle |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
HemaSphere
|
| title |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
|
| title_full |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
|
| title_fullStr |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
|
| title_full_unstemmed |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
|
| title_short |
T023 (0106) SAFETY AND EARLY RESPONSE TO THE FIRST 2 CYCLES OF BRENTUXIMAB VEDOTIN SUBSTITUTING VINCRISTINE IN THE OEPA/COPDAC REGIMEN FOR HIGH RISK PEDIATRIC HODGKIN LYMPHOMA (HL)
|
| title_sort |
t023 0106 safety and early response to the first 2 cycles of brentuximab vedotin substituting vincristine in the oepa copdac regimen for high risk pediatric hodgkin lymphoma hl
|
| url |
http://journals.lww.com/10.1097/01.HS9.0000547935.17200.58
|